PHARMACY

Pfizer appoints D’Amelio to COO position

BY Adam Kraemer

NEW YORK Pfizer announced that Frank D’Amelio, a senior executive with almost three decades of extensive operating and financial experience at AT&T, Lucent Technologies and Alcatel-Lucent, will become Pfizer’s senior vice president and chief financial officer effective mid-September.

D’Amelio, currently Senior Executive Vice President, Integration and chief administrative officer at Alcatel-Lucent, will join Pfizer’s Executive Leadership Team. He will have responsibility for all aspects of the company’s finances, including treasury, tax, the controller’s division and investor development. He succeeds Alan Levin, whose resignation from Pfizer was announced in May.

“We are very pleased that an executive with Frank’s skills, integrity, global experience and proven leadership is joining our management team,” said chairman and chief executive officer Jeff Kindler. “Through almost three decades at AT&T, Lucent and Alcatel-Lucent in both operating and financial roles, Frank was a senior executive in global companies undergoing the kind of rapid and complex changes we have undertaken at Pfizer in response to our own rapidly changing markets.”

“I am delighted to join Pfizer, a company with outstanding management, great people and what I truly believe is a very promising future in the forefront of medical innovation. In just a short period of time, Jeff has demonstrated strong leadership in setting a course for Pfizer to change the way it does business, so that it will be in the best possible position to take advantage of growing global demand for high-quality healthcare,” D’Amelio said. “Together with my finance colleagues, we’ll work hard to ensure that all aspects of Pfizer’s global financial strategy and operations help to advance these critical business imperatives.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

United Supermarkets to open first health care clinics in west Texas

BY Adam Kraemer

LUBBOCK, Texas United Supermarkets, a regional family-owned grocery chain with stores in 26 markets throughout north and west Texas is joining forces with Family Medicine Centers to offer a Living Well ExpressCare clinic in its Amarillo, Texas store beginning next month.

The clinic will offer primary medical services to store guests at United’s 45th and Bell location beginning Sept. 1. It will be located next to the pharmacy, allowing patients to get their prescriptions filled immediately at the same location.

United announced that similar facilities, the first in-store health clinics in west Texas, also are under construction in two United stores in Lubbock, as well as the new Market Street store being built in Frisco, near Dallas, according to the retailer.

“The need for accessible, affordable, high-quality health care in our country has never been greater, as studies indicate that nearly a third of the U.S. population does not have a family physician,” stated Mark Yowell, Specialty Division vice president of United Supermarkets. “[The clinics] “will allow us to focus attention on the wellness and nutrition products and services available in our stores.”

The facility will be open seven days a week, maintaining operating hours similar to those of the store’s pharmacy. It will be staffed by a licensed nurse practitioner or physician assistant under the supervision of a licensed physician.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

FDA approves Acatvis’ generic Duragesic patch

BY Drew Buono

MORRISTOWN, N.J. Actavis, the generic pharmaceutical company announced today that it has received approval from the Food and Drug Administration to market Fentanyl, the generic equivalent of the pain patch Duragesic.

President and chief executive officer Robert Wessmann said, “The addition of transdermal fentanyl is representative of our continued effort to expand the depth and breadth of our product portfolio, and highlights our product development expertise in specialty generic products.”

Annually, the brand and generic sales of Fentanyl in the U.S. were approximately $1.2 billion for the twelve months ending June 2007 according to IMS health data.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES